𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Toxogonin: Blood levels and side effects after intramuscular administration in man

✍ Scribed by Frederick R. Sidell; William A. Groff

Publisher
John Wiley and Sons
Year
1970
Tongue
English
Weight
542 KB
Volume
59
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

✦ Synopsis

Toxogonin, given intramuscularly to 10 healthy young pralidoxime (chloride and methanesulfonate) suggest further inmen in doses of 2.5-10 mg./kg., produced dose-related oxime whole quiry into toxogonin's therapeutic potential may be needed. blood levels of 6.3-26.5 mcg./ml. and hada plasma half-time of 82.8 min. Associated side effects included tachycardia, hypertension, Keyphrases 0 Toxogonin, intramuscular injection-oxime blood and a dose-independent symptom complex consisting of peroral levels 0 Plasma half-life-toxogonin 0 Dose relation, toxogoninwarmth, paresthesia and hypalgesia, and a menthol taste. Some plasma blood levels 0 Urinary excretion-toxogonin 0 Side published data on the relative effectiveness of toxogonin and effects-toxogonin

πŸ“œ SIMILAR VOLUMES

Blood cyanide levels in mice after admin
Blood cyanide levels in mice after administration of amygdalin
✍ Helene Z. Hill; Ronald Backer; George J. Hill II πŸ“‚ Article πŸ“… 1980 πŸ› John Wiley and Sons 🌐 English βš– 500 KB

## Abstract Oral doses of amygdalin and intraperitoneal (i.p.) doses of potassium cyanide (KCN) in the near‐lethal range were administered to CD2F1 female mice. Blood cyanide levels were then measured as a function of time. The maximum cyanide level after amygdalin administration was reached at abo

Evaluation of angiogenesis and side effe
Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ
✍ Ismo Vajanto; Tuomas T. Rissanen; Juha Rutanen; Mikko O. Hiltunen; Tiina T. Tuom πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 450 KB

## Abstract ## Background Recent studies have suggested the therapeutic potential of vascular endothelial growth factor (VEGF) gene therapy in ischemic skeletal muscle. However, only limited information is available about the effects of VEGF gene therapy in different regions of ischemic limbs, eff